{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:04:17Z","timestamp":1788613457947,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01516-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:32:07Z","timestamp":1767763927000},"page":"127-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Strategies After Discontinuation of Valproate By Females with Epilepsy of Child-Bearing Potential: An Insurance Claims Database Study in France and the United Kingdom"],"prefix":"10.1007","volume":"46","author":[{"given":"Sandrine","family":"Colas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Longin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Rouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Czekalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Carcaillon-Bentata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"10","key":"1516_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004.","journal-title":"CNS Drugs"},{"issue":"8","key":"1516_CR2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00415-020-09809-0","volume":"268","author":"M Toledo","year":"2021","unstructured":"Toledo M, Mostacci B, Bosak M, Jedrzejzak J, Thomas RH, Salas-Puig J, et al. Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective. J Neurol. 2021;268(8):2735\u201348. https:\/\/doi.org\/10.1007\/s00415-020-09809-0.","journal-title":"J Neurol"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0447.2005.00522","volume":"426","author":"CL Bowden","year":"2005","unstructured":"Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl. 2005;426:13\u201320. https:\/\/doi.org\/10.1111\/j.1600-0447.2005.00522.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"6","key":"1516_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1684\/epd.2019.1105","volume":"21","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21(6):497\u2013517. https:\/\/doi.org\/10.1684\/epd.2019.1105.","journal-title":"Epileptic Disord"},{"issue":"5","key":"1516_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1474-4422(18)30495-2","volume":"18","author":"LJ Stephen","year":"2019","unstructured":"Stephen LJ, Harden C, Tomson T, Brodie MJ. Management of epilepsy in women. Lancet Neurol. 2019;18(5):481\u201391. https:\/\/doi.org\/10.1016\/S1474-4422(18)30495-2.","journal-title":"Lancet Neurol"},{"issue":"11","key":"1516_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209279","volume":"102","author":"AM Pack","year":"2024","unstructured":"Pack AM, Oskoui M, Williams Roberson S, Donley DK, French J, Gerard EE, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice Guideline From the AAN, AES, and SMFM. Neurology. 2024;102(11):e209279. https:\/\/doi.org\/10.1212\/WNL.0000000000209279.","journal-title":"Neurology"},{"issue":"5","key":"1516_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","volume":"81","author":"D Battino","year":"2024","unstructured":"Battino D, Tomson T, Bonizzoni E, Craig J, Perucca E, Sabers A, et al. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024;81(5):481\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0258.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1516_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","volume":"81","author":"K Meador","year":"2008","unstructured":"Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1\u201313. https:\/\/doi.org\/10.1016\/j.eplepsyres.2008.04.022.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1516_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(12)70323-X.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1516_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/epi.15968","volume":"60","author":"Y Huber-Mollema","year":"2019","unstructured":"Huber-Mollema Y, Oort FJ, Lindhout D, Rodenburg R. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia. 2019;60(6):1069\u201382. https:\/\/doi.org\/10.1111\/epi.15968.","journal-title":"Epilepsia"},{"issue":"10282","key":"1516_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00246-4. (Erratum in: The Lancet. 2021 Apr 24;397(10284):1544. 10.1016\/S0140-6736(21)00886-2. Erratum in: The Lancet. 2021 May 15;397(10287):1808. 10.1016\/S0140-6736(21)01011-4).","journal-title":"Lancet"},{"issue":"5","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/00023210-200620050-00003","volume":"20","author":"B Tettenborn","year":"2006","unstructured":"Tettenborn B. Management of epilepsy in women of childbearing age: practical recommendations. CNS Drugs. 2006;20(5):373\u201387. https:\/\/doi.org\/10.2165\/00023210-200620050-00003.","journal-title":"CNS Drugs"},{"issue":"2","key":"1516_CR13","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.7861\/clinmedicine.18-2-s1","volume":"18","author":"RH Thomas","year":"2018","unstructured":"Thomas RH. Valproate: life-saving, life-changing. Clin Med (Lond). 2018;18(2):s1\u20138. https:\/\/doi.org\/10.7861\/clinmedicine.18-2-s1.","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"1516_CR14","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1111\/epi.13437","volume":"57","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP. Epilepsia. 2016;57(8):e173\u20137. https:\/\/doi.org\/10.1111\/epi.13437.","journal-title":"Epilepsia"},{"issue":"10","key":"1516_CR15","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1093\/brain\/awae128","volume":"147","author":"GK Mbizvo","year":"2024","unstructured":"Mbizvo GK, Bucci T, Lip GYH, Marson AG. Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy. Brain. 2024;147(10):3426\u201341. https:\/\/doi.org\/10.1093\/brain\/awae128.","journal-title":"Brain"},{"issue":"1","key":"1516_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/pn-2022-003685","volume":"23","author":"T Marson","year":"2023","unstructured":"Marson T. Maintaining equity and reducing risk when prescribing valproate: we still have a way to go. Pract Neurol. 2023;23(1):4\u20135. https:\/\/doi.org\/10.1136\/pn-2022-003685.","journal-title":"Pract Neurol"},{"key":"1516_CR17","unstructured":"European Medicines Agency. PRAC recommends new measures to avoid valproate in pregnancy. London: EMA, 2018 Contract No.: EMA\/67672\/2018."},{"issue":"8","key":"1516_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362. https:\/\/doi.org\/10.1002\/pds.4233.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1516_CR19","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(4):S149\u201367. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"3","key":"1516_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336. https:\/\/doi.org\/10.1093\/ije\/dyv098.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"1516_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565\u201374. https:\/\/doi.org\/10.1002\/pds.1230.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1516_CR22","unstructured":"Caisse nationale de l\u2019Assurance Maladie. Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les d\u00e9penses. Propositions de l\u2019Assurance Maladie pour 2017. Paris: CNAM, 2017 Contract No.: 20200221."},{"issue":"7","key":"1516_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pds.4556","volume":"27","author":"PO Bloti\u00e8re","year":"2018","unstructured":"Bloti\u00e8re PO, Weill A, Dalichampt M, Billionnet C, Mezzarobba M, Raguideau F, et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018;27(7):763\u201370. https:\/\/doi.org\/10.1002\/pds.4556.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1516_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/pds.4811","volume":"28","author":"C Minassian","year":"2019","unstructured":"Minassian C, Williams R, Meeraus WH, Smeeth L, Campbell OMR, Thomas SL. Methods to generate and validate a pregnancy register in the UK Clinical Practice Research Datalink primary care database. Pharmacoepidemiol Drug Saf. 2019;28(7):923\u201333. https:\/\/doi.org\/10.1002\/pds.4811.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.is.2015.04.007","volume":"53","author":"S Aghabozorgi","year":"2015","unstructured":"Aghabozorgi S, Shirkhorshidi AS, Wah TY. Time-series clustering\u2013a decade review. Inf Syst. 2015;53:16\u201338. https:\/\/doi.org\/10.1016\/j.is.2015.04.007.","journal-title":"Inf Syst"},{"issue":"24","key":"1516_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182413398","volume":"18","author":"J Vanoli","year":"2021","unstructured":"Vanoli J, Nava CR, Airoldi C, Ucciero A, Salvi V, Barone-Adesi F. Use of state sequence analysis in pharmacoepidemiology: a tutorial. Int J Environ Res Public Health. 2021;18(24):13398. https:\/\/doi.org\/10.3390\/ijerph182413398.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"1516_CR27","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00213-020-05618-5","volume":"237","author":"LV Panlilio","year":"2020","unstructured":"Panlilio LV, Stull SW, Bertz JW, Burgess-Hull AJ, Kowalczyk WJ, Phillips KA, et al. Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. Psychopharmacology. 2020;237(11):3369\u201381. https:\/\/doi.org\/10.1007\/s00213-020-05618-5.","journal-title":"Psychopharmacology"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jvb.2015.04.005","volume":"90","author":"K Dlouhy","year":"2015","unstructured":"Dlouhy K, Biemann T. Optimal matching analysis in career research: a review and some best-practice recommendations. J Vocat Behav. 2015;90:163\u201373. https:\/\/doi.org\/10.1016\/j.jvb.2015.04.005.","journal-title":"J Vocat Behav"},{"issue":"11","key":"1516_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113677","volume":"9","author":"D Dunkler","year":"2014","unstructured":"Dunkler D, Plischke M, Leffondr\u00e9 K, Heinze G. Augmented backward elimination: a pragmatic and purposeful way to develop statistical models. PLoS ONE. 2014;9(11):e113677. https:\/\/doi.org\/10.1371\/journal.pone.0113677.","journal-title":"PLoS ONE"},{"issue":"3","key":"1516_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze G, Wallisch C, Dunkler D. Variable selection\u2014a review and recommendations for the practicing statistician. Biom J. 2018;60(3):431\u201349. https:\/\/doi.org\/10.1002\/bimj.201700067. (Epub 2018 Jan 2).","journal-title":"Biom J"},{"key":"1516_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109718","volume":"153","author":"S Lallana","year":"2024","unstructured":"Lallana S, Fonseca E, Quintana M, Abraira L, Campos-Fern\u00e1ndez D, L\u00f3pez-Maza S, et al. Antiseizure medication withdrawal in adult patients with idiopathic generalized epilepsy: performance of two seizure recurrence prediction models. Epilepsy Behav. 2024;153:109718. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109718.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1516_CR32","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/epi.13853","volume":"58","author":"G Giussani","year":"2017","unstructured":"Giussani G, Bianchi E, Canelli V, Erba G, Franchi C, Nobili A, et al. Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia. 2017;58(9):1524\u201332. https:\/\/doi.org\/10.1111\/epi.13853.","journal-title":"Epilepsia"},{"key":"1516_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.seizure.2020.09.008","volume":"82","author":"A Qu\u00edlez","year":"2020","unstructured":"Qu\u00edlez A, Barald\u00e9s-Rovira M, Gallego Y, Sanahuja J, Mauri-Capdevila G, Purroy F. Risk-benefit assessment of treatment of epileptic women of childbearing age with valproic acid. Seizure. 2020;82:27\u201330. https:\/\/doi.org\/10.1016\/j.seizure.2020.09.008.","journal-title":"Seizure"},{"key":"1516_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107980","volume":"119","author":"A\u00c7 Atalar","year":"2021","unstructured":"Atalar A\u00c7, \u015eirin NG, Bebek N, Baykan B. Predictors of successful valproate withdrawal in women with epilepsy. Epilepsy Behav. 2021;119:107980. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107980.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1516_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209222","volume":"102","author":"E Cerulli Irelli","year":"2024","unstructured":"Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, et al. Predictors of seizure recurrence in women with idiopathic generalized epilepsy who switch from valproate to another medication. Neurology. 2024;102(9):e209222. https:\/\/doi.org\/10.1212\/WNL.0000000000209222.","journal-title":"Neurology"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01516-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:18Z","timestamp":1770179718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01516-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01516-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC\n                      is an employee of Sanofi and is a shareholder of this company.\n                      JL\n                      has received consultancy fees from Sanofi in the context of this work.\n                      XL\n                      is an employee of Sanofi and is a shareholder of this company.\n                      SK\n                      is an employee of Teva Pharmaceutical Industries Ltd.\n                      DB\n                      is an employee of Sanofi.\n                      MAB\n                      reports funding for her research institute (BPE) in the context of this study from the consortium who funded the study.\n                      MR\n                      reports funding for her research institute (BPE) in the context of this study from the consortium who funded the study.\n                      JC\n                      is an employee of Sanofi and is a shareholder of this company.\n                      PB\n                      : reports funding for his research institute (BPE) in the context of this study from the consortium who funded the study.\n                      EB\n                      reports funding for her research institute (BPE) in the context of this study from the consortium who funded the study.\n                      BS\n                      reports funding from Sanofi in the context of this work, consulting fees from Angelini and UCB, honoraria for lectures, presentations or educational events from Angelini, UCB and Desitin Pharma GmbH, and is chair of the board of trustees for the Michael Foundation.\n                      LCB\n                      reports funding for her research institute (BPE) in the context of this study from the consortium who funded the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The study received approval from the French ethical and scientific committee for research, studies and assessments in healthcare (CESREES) on 08\/OCT\/2020 and authorization by the French data protection authority (CNIL) on 1\/DEC\/2020 (reference: 920412). Since the SDNS is a pseudonymised database, individual patient consent was not required. An agreement was signed between Sanofi and CPRD to access the CPRD GOLD Raw Data and HES linkage under the ISAC protocol 20_000053.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable, as data used are pseudonimysed data and dont allow identification of the patients","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable, as data used are pseudonimysed data and dont allow identification of the patients","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code is not made available for this study","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The data can\u2019t be made available per ethics authorization restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"SC\n                      contributed to Conceptualization, Investigation, Methodology, Validation, Visualization, Writing\u2014review & editing.\n                      JL, XL, SK, DB, JG\n                      contributed to Writing\u2014review & editing.\n                      MAB\n                      contributed to Conceptualization, Software, Methodology, Formal analysis, Data curation, Investigation, Validation, Visualization, Writing\u2014review and editing.\n                      MR\n                      contributed to Conceptualization, Investigation, Methodology, Validation, Project administration, Visualization, Writing\u2014review & editing.\n                      PB\n                      contributed to Conceptualization, Investigation, Methodology, Validation, Visualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing.\n                      EB\n                      contributed to Investigation, Validation, Project administration, Visualization, Writing - review and editing.\n                      BS\n                      contributed to Conceptualization, Investigation, Validation, Writing - review and editing.\n                      LCB\n                      contributed to Conceptualization, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing - review & editing. All authors agreed on the journal for submission, all versions, and accepted responsibility and accountability for the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}